Caliermisol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Caliermisol in the following countries:
International Drug Name Search
Chloramphenicol succinat may be available in the countries listed below.
Chloramphenicol succinate sodium (a derivative of Chloramphenicol) is reported as an ingredient of Chloramphenicol succinat in the following countries:
International Drug Name Search
Taro-Sone may be available in the countries listed below.
Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Taro-Sone in the following countries:
International Drug Name Search
FOR EXTERNAL USE ONLY
Rx Only
Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate.
The structural formula is:
Each gram of Rosula (sodium sulfacetamide 10% and sulfur 4%) Foam contains 100 mg of sodium sulfacetamide and 40 mg of sulfur in an aqueous based foam vehicle containing cetyl alcohol NF, stearyl alcohol NF, polysorbate 60, methylparaben NF, propylparaben NF, propylene glycol NF, lactic acid USR purified water USR Also contains: Propellant HFA-134A (1,1,1,2- tetrafluoroethane).
Sodium sulfacetamide exhibits antibacterial activity. The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours.
The exact mechanism of the keratolytic activity of sulfur is unknown, but it is reported to result from the interaction of sulfur with the cysteine content of keratinocytes. Furthermore, in combination with sulfacetamide, sulfur has been reported to inhibit the growth of Propionibactehum acnes, thereby adding to the product's antibacterial activity and reducing associated inflammation.
Rosula® Foam is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.
Rosula® Foam is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Rosula® Foam is not to be used by patients with kidney disease.
Although rare, severe hypersensitivity reactions to sulfonamides include Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Hypersensitivity reactions may occur when a sulfonamide is readministered, irrespective of the route of administration. At the first sign of hypersensitivity or skin rash, discontinue use of this preparation. Particular caution should be employed if areas of involved skin to be treated are denuded or abraded.
FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of the reach of children. Contents under pressure. Do not puncture or incinerate container. Do not expose to temperatures above 120°F (49°C).
The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the skin. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility. If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy.
Avoid contact with eyes, eyelids, lips, and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops discontinue use and consult your physician.
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Category C. Animal reproduction studies have not been conducted with Rosula® Foam. It is also not known whether Rosula® Foam can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Rosula® Foam should be given to a pregnant woman only if clearly needed.
It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Rosula® Foam. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Rosula® Foam is administered to a nursing woman.
Safety and effectiveness in children under the age of 12 have not been established.
Although infrequent, sodium sulfacetamide may cause local irritation.
Wash affected areas before use, 1 to 2 times daily as directed by physician. Before each use, shake can vigorously, then gently tap the bottom of the can on a firm surface or in palm of other hand. Tap can 1-2 times, thenshake and tap again.
Invert can so nozzle points down. (Dispensing with the can held upright will cause a loss of the propellant and can affect product delivery.) Depress the actuator and dispense a small amount of foam (not more than a dollop the size of a golf ball).
Apply foam to the affected areas.
Avoid contact with the eyes.
Massage the dispensed foam into the affected areas and wait 1 to 2 minutes. Rinse thoroughly with water and pat dry. Treat the affected area 1 to 2 times daily, as directed by a physician.
Massage the foam into the affected areas 1 to 2 times daily, as directed by a physician.
Wipe off any excess foam from actuator after use.
Rosula® Foam is supplied in a 100 g, aluminum can: NDC 10337-669-99
CAUTION: Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120°F (49°C).
Store between 68° and 77°F (20° and 25°C).
Protect from freezing.
Store upright.
Mfd. for: PharmaDerm®
A division of Nycomed US Inc.
Melville, NY 11747 USA
www.pharmaderm.com
Mfd. by: Sciarra Laboratories Inc.
485-09 South Broadway
Hicksville, NY 11801
IF8668
R10/09
NDC 10337-669-99
PharmaDerm®
Rx only
Rosula®
(Sodium Sulfacetamide 10% and Sulfur 4%)
FOAM
FOR DERMATOLOGIC USE ONLY.
NOT FOR OPHTHALMIC USE.
100 g
| Rosula sodium sulfacetamide and sulfur aerosol, foam | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 08/03/2010 | ||
| Labeler - PharmaDerm, A division of Nycomed US Inc. (043838424) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Sciarra Laboratories Inc. | 824900369 | MANUFACTURE, PACK, ANALYSIS | |
Fungosten may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Fungosten in the following countries:
International Drug Name Search
Malastin may be available in the countries listed below.
Sulfadoxine is reported as an ingredient of Malastin in the following countries:
International Drug Name Search
Brozil may be available in the countries listed below.
Gemfibrozil is reported as an ingredient of Brozil in the following countries:
International Drug Name Search
